Theriva Biologics Inc. has announced a warrant inducement transaction with existing institutional investors, resulting in approximately $4.0 million in gross proceeds. Investors immediately exercised warrants to purchase up to 7,360,460 shares of common stock at a reduced exercise price of $0.54 per share. In exchange, these investors will receive new unregistered warrants to purchase up to 14,720,920 additional shares at the same exercise price. The new warrants will become exercisable upon stockholder approval and will expire five years after approval. Theriva Biologics intends to use the net proceeds for working capital and general corporate purposes. A.G.P./Alliance Global Partners served as exclusive financial advisor for the transaction.